Zirabev 400 MG in 16 ML Injection By PFIZER INC MPB

• First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
• Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product

ZIRABEV is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non–squamous non–small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

ZIRABEV is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

ZIRABEV, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.